Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Azad, Nilofer S

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Aug 2008 - 3709-14 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural

1527-7755

10.1200/JCO.2007.10.8332 doi


Administration, Oral
Adult
Aged
Angiogenesis Inhibitors--administration & dosage
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Benzenesulfonates--administration & dosage
Bevacizumab
Drug Administration Schedule
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Staging
Neoplasms--drug therapy
Niacinamide--analogs & derivatives
Ovarian Neoplasms--drug therapy
Phenylurea Compounds
Protein Kinase Inhibitors--administration & dosage
Pyridines--administration & dosage
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Sorafenib
Treatment Outcome
Vascular Endothelial Growth Factor A--antagonists & inhibitors
raf Kinases--antagonists & inhibitors